Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Vivos Therapeutics Inc
VVOS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.1347
-0.0059
-4.2%
Ult. Agg.: Oct 22, 5:59 AM
$0.1245
-0.0161
-11.45%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
Fusioni e acquisizioni:
SOD Sciences, Inc. was acquired by Vivos Therapeutics (VVOS) on Monday, October 19, 2026 for $12M
Vivos Therapeutics Financials
Vivos Therapeutics (VVOS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vivos Therapeutics Q2 EPS $(0.31) Beats $(0.36) Estimate, Sales $5.153M Miss $5.367M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share
Benzinga Newsdesk
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.
Avi Kapoor
PRO
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share
Benzinga Newsdesk
PRO
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
Benzinga Newsdesk
